Fifth Third Bancorp Acquires 2,265 Shares of Axsome Therapeutics, Inc. $AXSM

Fifth Third Bancorp boosted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 1,068.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,477 shares of the company’s stock after purchasing an additional 2,265 shares during the period. Fifth Third Bancorp’s holdings in Axsome Therapeutics were worth $452,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in AXSM. Vanguard Group Inc. lifted its stake in Axsome Therapeutics by 6.0% in the third quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock valued at $507,739,000 after purchasing an additional 235,626 shares during the last quarter. Franklin Street Advisors Inc. NC purchased a new stake in Axsome Therapeutics in the fourth quarter worth $1,826,000. Aberdeen Group plc raised its stake in shares of Axsome Therapeutics by 15.5% in the third quarter. Aberdeen Group plc now owns 94,648 shares of the company’s stock valued at $11,495,000 after buying an additional 12,732 shares during the period. TD Asset Management Inc raised its stake in shares of Axsome Therapeutics by 107.7% in the third quarter. TD Asset Management Inc now owns 44,192 shares of the company’s stock valued at $5,367,000 after buying an additional 22,914 shares during the period. Finally, Pictet Asset Management Holding SA lifted its position in shares of Axsome Therapeutics by 20.4% during the 4th quarter. Pictet Asset Management Holding SA now owns 436,063 shares of the company’s stock valued at $79,643,000 after buying an additional 73,925 shares during the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Wolfe Research began coverage on Axsome Therapeutics in a research note on Monday, February 23rd. They set an “outperform” rating and a $230.00 price target for the company. Royal Bank Of Canada upped their price objective on shares of Axsome Therapeutics from $242.00 to $302.00 and gave the company an “outperform” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Monday, April 20th. Piper Sandler reiterated an “overweight” rating and issued a $258.00 target price on shares of Axsome Therapeutics in a research note on Monday. Finally, Mizuho boosted their price target on shares of Axsome Therapeutics from $228.00 to $310.00 and gave the company an “outperform” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Axsome Therapeutics has an average rating of “Moderate Buy” and an average price target of $251.26.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $222.63 on Thursday. The business’s 50-day moving average price is $172.69 and its two-hundred day moving average price is $164.03. The stock has a market cap of $11.46 billion, a P/E ratio of -59.69 and a beta of 0.59. The company has a quick ratio of 1.48, a current ratio of 1.39 and a debt-to-equity ratio of 2.27. Axsome Therapeutics, Inc. has a twelve month low of $96.09 and a twelve month high of $234.29.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.41). The company had revenue of $191.20 million for the quarter, compared to the consensus estimate of $191.10 million. Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The company’s revenue was up 57.4% compared to the same quarter last year. As a group, equities analysts predict that Axsome Therapeutics, Inc. will post -1.19 EPS for the current fiscal year.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, insider Ari Maizel sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $182.42, for a total transaction of $1,368,150.00. Following the sale, the insider owned 7,500 shares in the company, valued at $1,368,150. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Mark L. Jacobson sold 233 shares of Axsome Therapeutics stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $228.18, for a total value of $53,165.94. Following the sale, the chief operating officer directly owned 4,517 shares of the company’s stock, valued at approximately $1,030,689.06. This trade represents a 4.91% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 72,628 shares of company stock valued at $12,205,662. Insiders own 20.60% of the company’s stock.

Axsome Therapeutics News Roundup

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Strong commercial traction — Axsome reported Q1 product revenue of $191.2M, up ~57% year‑over‑year driven by AUVELITY and SUNOSI, which supports the company’s growth narrative and near‑term cash generation. Read More.
• Positive Sentiment: Analyst optimism and price‑target lifts — multiple firms raised targets (notably Mizuho to $310, Wells Fargo to $255, Baird and others), and coverage remains skewed positive, which can support upside momentum and bid interest. Read More.
• Neutral Sentiment: Management outreach scheduled — Axsome will participate in May investor conferences (including a BofA fireside chat), offering additional investor access but uncertain immediate impact. Read More.
• Neutral Sentiment: Earnings detail and call transcript available — analysts are parsing the conference call and guidance implications; deeper read may resolve questions around sales cadence and expense trajectory. Read More.
• Negative Sentiment: Profitability miss — GAAP EPS of ($1.26) missed consensus (~$0.85 loss), and negative margins/ROE highlight near‑term profitability and cost structure concerns despite revenue strength. Read More.
• Negative Sentiment: Insider selling — COO Mark Jacobson disclosed sales (large blocks on May 4 and a smaller sale May 5), which may raise short‑term sentiment questions even though filers report remaining holdings. Read More.
• Negative Sentiment: Durability concerns — some analysts/commentators question sequential product sales trends and achievability of peak revenue assumptions, which could temper multiple expansion absent clearer margin improvements. Read More.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.